Impact of interferon-α in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): First data from the immunomonitoring

Journal of Immunotherapy

Volumn 30, Issue 1, 2007, Pages 108-115

  Schmidt, Jan ^a   Jäger, Dirk ^a   Hoffmann, Kartin ^a   Büchler, Markus W ^a   Märten, Angela ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Department of Surgery ^*  (Germany)

Author keywords

Chemoradioimmunotherapy; NK cells; Pancreatic carcinoma

Indexed keywords

CD40 ANTIGEN; CISPLATIN; CYTOKINE; FLUOROURACIL; FOLINIC ACID; GRANZYME B; INTERLEUKIN 12; MUCIN 1; RECOMBINANT ALPHA2B INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ADULT; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EFFECTOR CELL; ENZYME RELEASE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MEMORY T LYMPHOCYTE; MONOCYTE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; CYTOKINES; FLUOROURACIL; FOLIC ACID; GRANZYMES; HUMANS; IMMUNOPHENOTYPING; INTERFERON-ALPHA; KILLER CELLS, NATURAL; LEUKOCYTES; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES;

EID: 33845981502     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000211317.15278.27     Document Type: Article

References (32)

1. Raraty MG, Magee CJ, Ghaneh P, et al. New techniques and agents in the adjuvant therapy of pancreatic cancer. Acta Oncol. 2002;41:582-595.
2. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2003;185:476-480.
3. Knaebel H, Märten A, Schmidt J, et al. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma - CapRI [ISRCTN62866759]. BMC Cancer. 2005;5:37.
4. Belardelli F, Ferrantini M, Proietti E, et al. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13:119-134.
5. Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Semin Oncol. 2002;29(Suppl. 7):18-26.
6. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA. 1994;91:1198-1205.
7. Delcayre AX, Salas F, Mathur S, et al. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor. EMBO J. 1991;10:919-926.
8. Domanski P, Witte M, Kellum M, et al. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J Biol Chem. 1995;270:21606-21611.
9. Mogensen KE, Lewerenz M, Reboul J, et al. The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res. 1999;19:1069-1098.
10. Iacopino F, Ferrandina G, Scambia G, et al. Interferons inhibit EGF-stimulated cell growth and reduce EGF binding in human breast cancer cells. Anticancer Res. 1996;16:1919-1924.
11. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998;58:2489-2499.
12. Holsti LR, Mattson K, Niiranen A, et al. Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1987;13:1161-1166.
13. Kurzrock R, Talpaz M, Guttermann J. Biologic therapy of cancer. In: DeVita V, Hellmann S, Rosenberg S, eds. Interferons: Clinical Applications. Philadelphia: Lippincott; 1991.
14. Decatris M, Santhanam S, O'Byrne K. Potential of interferon-alpha in solid tumours: part 1. BioDrugs. 2002;16:261-281.
15. Solorzano CC, Hwang R, Baker CH, et al. Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin Cancer Res. 2003;9:1858-1867.
16. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med. 1999;189:521-530.
17. Matikainen S, Sareneva T, Ronni T, et al. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood. 1999;93:1980-1991.
18. Paquette RL, Hsu NC, Kiertscher SM, et al. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol. 1998;64:358-367.
19. Ma J, Patrut E, Schmidt J, et al. Synergistic effects of Interferon-alpha in combination with Chemoradiation on human pancreatic adenocarcinoma. World J Gastroenterol. 2005;11:1521-1528.
20. Schmidt J, Patrut E, Knaebel H-P, et al. Immunomodulatory impact of Interferon-alpha in combination with chemotherapy of pancreatic adenocarcinoma (CapRI). Cancer Immunol Immunother. 2006. [Epub ahead of print].
21. Polak L, Turk JL. Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature. 1974;249:654-656.
22. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res. 2002;62:2353-2358.
23. Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8T, cells. J Immunol. 2003;170:4905-4913.
24. Lake R, Robinson B. Immunotherapy, and chemotherapy - a practical partnership. Nat Rev Cancer. 2005;5:397-405.
25. Neuhaus P, Oettle H, Post S, et al. A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs observation in patients with resected pancreatic cancer. 2005; Abstract 4013 ASCO.
26. Neoptolemos J, Stocken D, Friess H, et al. The final results of the European Study Group for Pancreatic Cancer randomized controlled trial of adjuvant chemoradiotherapy and chemotherapy in patients with resectable pancreatic canecr. N Engl J Med. 2004;350:1200-1210.
27. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 2002;25:97-138.
28. Masopust D, Vezys V, Marzo AL, et al. Preferential localization of effector memory cells in nonlymphoid tissue. Science. 2001;291:2413-2417. Epub 2001, Mar 1.
29. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4:225-234. Epub 2003, Feb 3.
30. Niedergethmann M, Rexin M, Hildenbrand R, et al. Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma. Am J Surg Pathol. 2002;26:1578-1587.
31. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407:784-788.
32. Rovere P, Sabbadini MG, Vallinoto C, et al. Delayed clearance of apoptotic lymphoma cells allows cross-presentation of intracellular antigens by mature dendritic cells. J Leukoc Biol. 1999;66:345-349.